2aoa

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="2aoa" size="450" color="white" frame="true" align="right" spinBox="true" caption="2aoa, resolution 1.99&Aring;" /> '''Crystal structures ...)
Line 1: Line 1:
-
[[Image:2aoa.gif|left|200px]]<br />
+
[[Image:2aoa.gif|left|200px]]<br /><applet load="2aoa" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="2aoa" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="2aoa, resolution 1.99&Aring;" />
caption="2aoa, resolution 1.99&Aring;" />
'''Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain'''<br />
'''Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain'''<br />
==Overview==
==Overview==
-
The high-affinity binding of the growth factor receptor-bound protein 2, (Grb2) SH2 domain to tyrosine-phosphorylated cytosolic domains of receptor, tyrosine kinases (RTKs) is an attractive target for therapeutic, intervention in many types of cancer. We report here two crystal forms of, a complex between the Grb2 SH2 domain and a potent, non-phosphorus-containing macrocyclic peptide mimetic that exhibits, significant anti-proliferative effects against erbB-2-dependent breast, cancers. This agent represents a "second generation" inhibitor with, greatly improved binding affinity and bio-availability compared to its, open-chain counterpart. The structures were determined at 2.0A and 1.8A, with one and two domain-swapped dimers per asymmetric unit, respectively., The mode of binding and specific interactions between the protein and the, inhibitor provide insight into the high potency of this class of, macrocylic compounds and may aid in further optimization as part of the, iterative rational drug design process.
+
The high-affinity binding of the growth factor receptor-bound protein 2 (Grb2) SH2 domain to tyrosine-phosphorylated cytosolic domains of receptor tyrosine kinases (RTKs) is an attractive target for therapeutic intervention in many types of cancer. We report here two crystal forms of a complex between the Grb2 SH2 domain and a potent non-phosphorus-containing macrocyclic peptide mimetic that exhibits significant anti-proliferative effects against erbB-2-dependent breast cancers. This agent represents a "second generation" inhibitor with greatly improved binding affinity and bio-availability compared to its open-chain counterpart. The structures were determined at 2.0A and 1.8A with one and two domain-swapped dimers per asymmetric unit, respectively. The mode of binding and specific interactions between the protein and the inhibitor provide insight into the high potency of this class of macrocylic compounds and may aid in further optimization as part of the iterative rational drug design process.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
2AOA is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with S1S and P33 as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2AOA OCA].
+
2AOA is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=S1S:'>S1S</scene> and <scene name='pdbligand=P33:'>P33</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2AOA OCA].
==Reference==
==Reference==
Line 17: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Burke, T.R.]]
+
[[Category: Burke, T R.]]
[[Category: Phan, J.]]
[[Category: Phan, J.]]
-
[[Category: Shi, Z.D.]]
+
[[Category: Shi, Z D.]]
-
[[Category: Waugh, D.S.]]
+
[[Category: Waugh, D S.]]
[[Category: P33]]
[[Category: P33]]
[[Category: S1S]]
[[Category: S1S]]
Line 27: Line 26:
[[Category: peptide mimetic]]
[[Category: peptide mimetic]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:53:12 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:29:18 2008''

Revision as of 14:29, 21 February 2008


2aoa, resolution 1.99Å

Drag the structure with the mouse to rotate

Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain

Contents

Overview

The high-affinity binding of the growth factor receptor-bound protein 2 (Grb2) SH2 domain to tyrosine-phosphorylated cytosolic domains of receptor tyrosine kinases (RTKs) is an attractive target for therapeutic intervention in many types of cancer. We report here two crystal forms of a complex between the Grb2 SH2 domain and a potent non-phosphorus-containing macrocyclic peptide mimetic that exhibits significant anti-proliferative effects against erbB-2-dependent breast cancers. This agent represents a "second generation" inhibitor with greatly improved binding affinity and bio-availability compared to its open-chain counterpart. The structures were determined at 2.0A and 1.8A with one and two domain-swapped dimers per asymmetric unit, respectively. The mode of binding and specific interactions between the protein and the inhibitor provide insight into the high potency of this class of macrocylic compounds and may aid in further optimization as part of the iterative rational drug design process.

Disease

Known diseases associated with this structure: Central hypoventilation syndrome, congenital OMIM:[100790], Haddad syndrome OMIM:[100790]

About this Structure

2AOA is a Single protein structure of sequence from Homo sapiens with and as ligands. Full crystallographic information is available from OCA.

Reference

Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain., Phan J, Shi ZD, Burke TR Jr, Waugh DS, J Mol Biol. 2005 Oct 14;353(1):104-15. PMID:16165154

Page seeded by OCA on Thu Feb 21 16:29:18 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools